{"entity":{"id":"anergy","kind":"term","name":"T-cell anergy","aka":[],"tldr":"A living T cell can remain less responsive after an antigen encounter. A weak test result alone does not establish anergy.","summary":"Anergy is antigen-related reduced responsiveness that persists into a later controlled response test. In Jenkins and Schwartz's mouse and T-cell-clone experiments, chemically altered presenting cells induced reduced responsiveness to subsequent antigen stimulation with normal presenting cells. Macian and colleagues identified an NFAT-associated anergy gene programme in mechanistic experiments. These findings are model evidence, not a universal tumour-cell classifier.\n\nExhaustion is a distinct differentiation programme associated with persistent stimulation. Anergy, exhaustion, external suppression, absent antigen-specific cells and assay failure are different possible explanations for a low response. Low interleukin-2 alone leaves the mechanism unresolved. Check specificity, viable-cell recovery, stimulus controls, responsive comparators and response history; measure division and cytokine responses under matched conditions. Laboratory rescue does not establish tumour recognition, safe killing or clinical benefit.","asOf":"2026-11-09","links":[{"label":"Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo.","url":"https://pubmed.ncbi.nlm.nih.gov/3029267/"},{"label":"Transcriptional mechanisms underlying lymphocyte tolerance.","url":"https://pubmed.ncbi.nlm.nih.gov/12086671/"},{"label":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection.","url":"https://pubmed.ncbi.nlm.nih.gov/17950003/"},{"label":"Review (PubMed 12471050)","url":"https://pubmed.ncbi.nlm.nih.gov/12471050/"},{"label":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.","url":"https://pubmed.ncbi.nlm.nih.gov/7636184/"},{"label":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.","url":"https://pubmed.ncbi.nlm.nih.gov/30778252/"}],"tags":[],"related":["t-cell"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Anergy is persistent reduced antigen-driven responsiveness after a defined antigen encounter, assessed with a suitable later challenge. It is not simply resting, a naive identity, missing support at one encounter or failure to divide now. Altered-presenting-cell induction followed by normal-presenting-cell retesting in mouse clones supports this distinction.","In defined mechanistic experiments, unbalanced calcium signalling and NFAT without cooperative AP-1 promoted an anergy-associated gene programme. Reduced IL-2, a response-supporting cytokine, can accompany anergy. Signal strength, inhibitory context and experimental definition matter; inadequate costimulation is an example rather than a universal diagnosis.","Low IL-2 or a negative ELISpot response alone does not establish anergy. Confirm antigen-specific cells, viable-cell recovery, matched stimulus and responsive comparators, response history and relevant pathway perturbations. Report dividing-cell fractions or cytokine concentration with assay units and conditions. Missing recognition, damaged preparations, suppression or exhaustion remain alternatives.","Anergy can contribute to tolerance of mature immune cells. Protective restraint and tumour immune escape can overlap; changing a laboratory response does not establish restored specificity, tumour access, safe killing or clinical benefit.","Anergy and exhaustion are distinct programmes, not compulsory successive stages or interchangeable labels for dysfunction. Dysfunction is a broader description that may also include senescence, external suppression and missing recognition. Classic clonal anergy often limits growth and IL-2 while retaining effector functions and can respond to added IL-2; adaptive tolerance has broader deficits and can reverse after antigen removal. These distinctions come from model and review evidence, not clinical cutoffs.","Fictional independent populations A and B share verified specificity and suitable later stimulation. A has altered initial support followed by a controlled persistent defect; B has persistent stimulation with several functional deficits and compatible programme evidence. These support anergy-compatible and exhaustion-compatible explanations respectively. C with only low IL-2 remains unassigned. Viability, specificity and positive controls are necessary; no one control establishes state and no A-to-B transition or checkpoint-rescue prediction follows.","Source scope: teaching synthesis checked against the cited abstracts and specified accessible primary text on 9 November 2026; fictional examples are not clinical observations or treatment-selection rules."],"category":"Immunology"},"route":"/terms/anergy/","neighbours":{"term":[{"id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/"}]}}